Objectives: Chronic hepatitis C virus (CHC) infection is treated with interferon/ribavirin, but only a subset of patients respond. The molecular mechanism of interferon resistance is not well undertstood. We previously reported that treatment nonresponders have marked pre-treatment upregulation of a subset of interferon stimulated genes (ISGs) in their livers, including ISG15 (Chen, et al. Gastroenterology 2005) and discovered ISG15/USP18 pathway is involved in interferon resistance (Randall, et al. Gastroenterology 2006). Here, we study the effect of ISG15 on HCV production in J6/JFH1 culture system. Methods: ISG15 expression and its conjugation (ISGylation) was manipulated in two ways: up-regulated by plasmid transfection and inhibited by silencing the E1 activating enzyme Ube1L using specific SiRNA. The effect of increased or decreased ISG15/ISGylation on HCV RNA replication and viral particle production was monitored by real-time PCR and NS5A staining, respectively. Results: Overexpression of ISG15 increased ISGylation in Huh7.5 cells and promoted HCV RNA replication and virion secretion. Silencing Ube1L ablated ISGylation and inhibited HCV production. This pro-HCV effect of ISG15 is not mediated through extracellular free form ISG15 nor from perturbing the Jak/STAT signaling pathway. Conclusions: Contrary to many published studies on the antiviral activity of ISG15 in a number of viral models, ISG15 is a pro-HCV molecule in vitro. This finding may help to explain why increased ISG15 in the pretreatment liver tissue is correlated with treatment failure, and suggests that manipulating ISG15 may be a potential approach for HCV therapy. 
Conclusions: This study suggests that the carbapenems provide the greatest likelihood of clinical success for the Enterobacteriaceae, and combination therapy might be needed when choosing empirical therapy, especially when A. baumannii or P. aeruginosa are suspected.
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